Dyne Therapeutics has unveiled promising preclinical data demonstrating the FORCE platform’s ability to effectively cross the blood-brain barrier (BBB) and achieve significant knockdown of MAPT RNA in the central nervous system (CNS). This advancement will be presented at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The data highlight the platform’s potential not only in treating neuromuscular diseases like Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) but also in addressing neurological conditions characterized by tauopathies, such as Alzheimer’s disease.

The findings indicate that both Conjugate 1 and Conjugate 2, which utilize a TfR1-binding antibody fragment (Fab) conjugated to MAPT siRNA, achieved approximately 75% MAPT RNA knockdown in preclinical models, including both mice and nonhuman primates (NHPs). Notably, Conjugate 2, optimized for enhanced CNS delivery, demonstrated robust and consistent delivery across various brain regions, suggesting a significant advancement in therapeutic strategies targeting CNS-related diseases. This capability is particularly relevant given the pathological role of tau protein accumulation in neurodegenerative disorders.

The implications of these results are substantial for the field of gene therapy and drug development. The ability to achieve robust CNS delivery using the FORCE platform could accelerate the exploration of therapeutic candidates for tauopathies, potentially shifting current paradigms in the treatment of neurological diseases. Furthermore, this progress may streamline the development timelines for future clinical applications, enhancing the prospect of effective therapies for patients suffering from these debilitating conditions.

Source: globenewswire.com